Renal Cancer - Results from #880

Effect of smoking, hypertension and lifestyle factors on kidney cancer - perspectives for prevention and screening programmes. June 19, 2023

Surgical Management of Localized Disease and Small Renal Masses. June 19, 2023

Robot-assisted partial nephrectomy for complex renal tumors: Analysis of a large multi-institutional database. June 16, 2023

Randomized Controlled Feasibility Trial of Robot-assisted Versus Conventional Open Partial Nephrectomy: The ROBOCOP II Study. June 16, 2023

New-onset Chronic Kidney Disease After Surgery for Localised Renal Masses in Patients with Two Kidneys and Preserved Renal Function: A Contemporary Multicentre Study. June 15, 2023

The Metastatic Risk of Renal Cell Carcinoma by Primary Tumor Size and Subtype. June 15, 2023

TROAP Promotes the Proliferation, Migration, and Metastasis of Kidney Renal Clear Cell Carcinoma with the Help of STAT3. June 14, 2023

Adjuvant therapy for renal cell carcinoma in 2023: hopes and disappointments. June 14, 2023

Impact of diabetes and chronic kidney disease on active surveillance outcomes for small renal masses: A cohort study. June 13, 2023

A Contemporary Clinicopathologic Analysis of Patients With Renal Cell Carcinoma and Vena Cava Involvement. June 13, 2023

The Current Role of Lymph Node Dissection in Nonmetastatic Localized Renal Cell Carcinoma. June 12, 2023

Pre-treatment metastatic growth rate is associated with clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab. June 12, 2023

Renal Cell Carcinoma of Variant Histology: Biology and Therapies. June 9, 2023

Adverse Effects of Immune-Checkpoint Inhibitors: A Comprehensive Imaging-Oriented Review. June 9, 2023

Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma. June 8, 2023

Percutaneous radiofrequency ablation is an effective treatment option for small renal masses, comparable to partial nephrectomy. June 8, 2023

Cost-effectiveness of Nivolumab Plus Cabozantinib Versus Cabozantinib as First-Line Treatment of Metastatic Renal Cell Carcinoma. June 7, 2023

A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma. June 7, 2023

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial June 6, 2023

Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors. June 6, 2023

Page 45 of 456